title: Lack of strong effect modification by NFE2L2/CYP3A5/ABO of the risk of venous thrombosis associated with oral hormone therapy.
authors.forename: M
authors.initials: M
authors.lastname: Blondon
authors.forename: K L
authors.initials: KL
authors.lastname: Wiggins
authors.forename: L B
authors.initials: LB
authors.lastname: Harrington
authors.forename: B M
authors.initials: BM
authors.lastname: Psaty
authors.forename: N L
authors.initials: NL
authors.lastname: Smith
mesh_terms: D000017:ABO Blood-Group System / Q000378:metabolism*; D000284:Administration, Oral; D000368:Aged; D000483:Alleles; D016022:Case-Control Studies; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism*; D005260:Female; D005787:Gene Frequency; D014644:Genetic Variation; D006728:Hormones / Q000008:administration & dosage; D006801:Humans; D008875:Middle Aged; D051267:NF-E2-Related Factor 2 / Q000378:metabolism*; D020641:Polymorphism, Single Nucleotide; D017698:Postmenopause; D011655:Pulmonary Embolism / Q000097:blood; D012044:Regression Analysis; D012307:Risk Factors; D020246:Venous Thrombosis / Q000097:blood; D014861:Washington
chemical_list: D000017:ABO Blood-Group System; D006728:Hormones; D051267:NF-E2-Related Factor 2; C495635:NFE2L2 protein, human; C510164:CYP3A5 protein, human; D051544:Cytochrome P-450 CYP3A